Organic Active Ingredients TRIZ Cases

Biodegradable particles release chemotherapeutic agents locally to target cancer cells, reducing wound healing interference.

Formula I compounds inhibit ASK1 and ASK2 signaling to treat autoimmune, inflammatory, cardiovascular, and neurodegenerative diseases.

Conjugating cisplatin with amino acids targets LAT1 transporters to concentrate drug at tumor sites while reducing systemic toxicity.

Novel phenylacetamide compounds inhibit Rho kinases, addressing unmet needs for treating resistant cardiovascular diseases.

Solvent extraction of unfermented beans followed by milling reduces bitterness while maintaining high polyphenol concentration.

A water and ethanol co-solvent system precipitates gefitinib Form 1, reducing solvent consumption while maintaining batch uniformity.

Thiol linkers join hyaluronic acid to flavonoids, forming stable conjugates that autoxidize into hydrogels with improved bioavailability.

Combination therapies neutralize TNFR1, TRAIL-R, and CD95 to block cell death pathways, addressing limitations of single-agent TNF inhibitors.

Segmented fused pyrimidine structures achieve selective RET inhibition, eliminating off-target side effects from non-specific kinase activity.

Novel CGRP receptor antagonist compounds with specific ring systems and linker groups treat migraine disorders by improving treatment effectiveness.

Granules with controlled surface pores accommodate micronized drugs to enhance loading capacity and maintain formulation flow properties.

Introducing substituted guanidine groups into imidazoquinoline cores resolves the trade-off between structural complexity and cytokine induction capability.

Ion implantation embeds boron or gadolinium into nanodiamonds, increasing tumor loading capacity while protecting normal cells from damage.

Benzoxazolone urea scaffolds modulate ceramide levels by optimizing R1-R6 substituents to resolve potency and stability trade-offs.

Novel TRPC6 inhibitor compounds modulate ion flux to resolve therapeutic effectiveness gaps in treating hypertension and fibrotic disorders.

Recrystallizing free prasugrel removes OXTP impurities before salt formation, achieving 95% purity.

Combining HE4 inhibition with immune checkpoint blockade sensitizes cells to chemotherapy, addressing limited efficacy in single-agent cancer therapies.

Tetracyclic pyridone compounds reduce viral load and subviral particle abundance while preventing drug-resistant mutant persistence.

SNS-595 dosing regimens resolve efficacy and toxicity trade-offs through precise parameter adjustments.

A sterile viscous gel adheres to sinus mucosa, preventing drug waste and reducing systemic side effects.

Cyclic hydrazone compounds suppress IL-12 and TH1 cell proliferation, addressing persistent pro-inflammatory cytokine production in autoimmune treatments.

An acetal ester linker in the aptamer-triptolide conjugate overcomes low acid sensitivity of prior art by cleaving in the acidic lysosomal environment.

Segmenting broad inhibition into selective targeting resolves the specificity trade-off while maintaining therapeutic reliability.

Novel biphenyl triazol structures achieve nanomolar IC50 values for STIM1/Orai1 modulation without cytotoxicity.

Modified carnosine esters scavenge reactive species while resisting enzymatic degradation, restoring cellular function in pancreatic beta-cells.

Segmented gemcitabine instillation overcomes short dwell time limitations, reducing systemic toxicity while sustaining therapeutic tissue levels.

A composition using fucosterol and Sargassum fulvellum extracts to enhance muscle protein synthesis via p-mTOR activation.

pH-controlled aqueous GLYX-13 formulations prevent degradation in solution, enabling efficient blood-brain barrier transport for treating CNS disorders.

N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides inhibit serum and glucocorticoid regulated kinase 1.

Formula I compounds reduce viral load and extend protection windows against mutating strains by targeting conserved regions.

Steviol glycosides combined with carbohydrates and proteins accelerate glycogen re-synthesis, resolving prolonged recovery times after exhaustive exercise.

Ethyl cellulose formulations incorporate 2-mercaptobenzimidazole as an intermediary antioxidant to suppress impurity generation during long-term storage.

Combining phenoxypyrimidinone compounds with insulin potentiates glucose control, reducing injection frequency.

Acid addition salts convert unstable hydroxynorketamine oils into crystalline solids with high aqueous solubility.

Formula I compounds inhibit AhR activity, resolving the trade-off between detoxification and pro-cancerogen metabolism in cancer treatment.

Macrocyclic compounds featuring a fluorinated pyrimidine core and substituted sulfonyl-methylene group enhance potency as CDK9 inhibitors.

CXCL12 biomarker analysis selects tipifarnib candidates for angioimmunoblastic T-cell lymphoma, improving response rates.

An ethanol and surfactant mixture solubilizes a low-solubility active compound, maintaining chemical stability for at least 24 hours after dilution.

Segmented substituted pyrimidine derivatives resist specific kinase families, resolving the trade-off between broad treatment coverage and off-target effects.

Patsnap Eureka TRIZ case shows recombinant EGFL7 antibodies targeting acute myeloid leukemia blasts to overcome poor prognostic accuracy.

Novel 23-yne vitamin D3 derivative enhances bone mineral density without excessive serum calcium elevation.

Thermosensitive bio-adhesive hydrogel encapsulates renal stone fragments and protects urothelium during lithotripsy procedures.

Direct filling of nascent lipid nanoparticles into primary packaging containers followed by freeze drying eliminates deep-freeze storage requirements.

A pomalidomide pharmaceutical composition uses specific binders and fillers to enhance drug dissolution rates within oral capsules.

Developing stable crystalline hydrates of FTY720 hydrochloride resolves polymorphism issues, ensuring consistent therapeutic efficacy.

Alternating FGFR and PLK1 inhibitor cycles resolves acquired resistance while maintaining manageable treatment complexity to enhance tumor regression.

Bicyclic amine compounds act as positive allosteric modulators for the GABAA alpha5 receptor subtype.